1.459USD+0.66%Mkt Cap: 5.05M USDP/E: —Last update: 2026-06-01
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap5.05M USD
Enterprise Value-6.29M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-12.88M USD
Revenue/Share—
Last Price1.459 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.59
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.18
EPS (TTM)-29.01
EPS (Forward)-0.88
52W Range
1.1900% of range85.80
52W High85.80 USD
52W Low1.190 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE1012.50%
ROA-459.80%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.52M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-65.13%
Net Debt-9.55M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.53
Current Ratio1.79
Quick Ratio1.76
Book Value/Sh7.616 USD
Cash/Share4.402 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJun 21, 2019
Splits
Last Split1:3
Split DateMar 10, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.3.49M
Float2.12M
Insiders2.89%
Institutions8.10%
Short Interest
Short Ratio0.0d
Short % Float1.62%
Short % Out.1.62%
Shares Short37.85K
Short (prev mo.)250.96K
Technical
SMA 504.395 (-66.8%)
SMA 2008.427 (-82.7%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)2.48M
Avg Vol (10d)5.84M
Technical Indicators
RSI (14)33.6
MACD-0.7496
MACD Signal-0.8050
MACD Hist.+0.0555
BB Upper3.524 USD
BB Middle2.099 USD
BB Lower0.6727 USD
BB Width135.89%
ATR (14)0.4548 USD
Vol Ratio (20d)0.22x